Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.55 |
| ▸ | DRD1 | P21728 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | HTR2C | P28335 | 3/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.55 |
| ▸ | HRH1 | P35367 | 3/20 | 0.55 |
| ▸ | HTR2B | P41595 | 3/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368614 | 1.00 | DRD2 (1.00) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| Hydrochloric Acid SCHEMBL1943859 | 0.99 | DRD2 (0.97) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| Hydrochloric Acid SCHEMBL8507 | 0.99 | DRD2 (0.97) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| Sulfuric Acid SCHEMBL4143302 | 0.93 | DRD2 (0.87) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| Phosphoric Acid SCHEMBL4151583 | 0.92 | DRD2 (0.85) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| SCHEMBL4146089 | 0.91 | DRD2 (0.83) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| SCHEMBL8022151 | 0.89 | DRD2 (0.80) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| SCHEMBL11555179 | 0.86 | DRD2 (0.76) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| SCHEMBL12395990 | 0.86 | DRD2 (0.74) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| SCHEMBL2159879 | 0.86 | DRD2 (0.74) | DRD2CHRM2ADRA2ACHRM1ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389510-B2 | Crystalline forms | ASTRAZENECA AB (SE) | 2013-03-05 | — | — | US | claimed |
| US-20110237568-A1 | CRYSTALLINE FORMS | BLACK SIMON N | 2011-09-29 | — | — | US | claimed |
| US-20110144088-A1 | METHOD OF TREATING SLEEP DISORDERS | DAVIS PATRICIA C | 2011-06-16 | — | — | US | claimed |
| US-20110144089-A1 | METHOD OF TREATING SCHIZOPHRENIA AND OTHER DISORDERS | ASTRAZENECA AB (SE) | 2011-06-16 | — | — | US | claimed |
| US-20110136786-A1 | METHOD OF TREATING MOOD DISORDERS | DAVIS PATRICIA C | 2011-06-09 | — | — | US | claimed |
| US-20110136785-A1 | METHOD OF TREATMENT | DAVIS PATRICIA C | 2011-06-09 | — | — | US | claimed |
| US-20110136784-A1 | Method of Treating Anxiety Disorders | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | claimed |
| US-7902355-B2 | Condensation of 10H-dibenzo-[b,f][1,4]-thiazepin-11-one with a piperazine derivative in the presence of a titanium alkoxide catalyst; Titanium catalyst easier to handle, have low toxicity, not chlorinated, much less harmful for the environment | UNION QUIMICO-FARMACEUTICA S.A. (ES) | 2011-03-08 | — | — | US | claimed |
| EP-1781646-B1 | PROCESS FOR THE PREPARATION OF 11-(4-[2-(2-HYDROXYETHOXY)ETHYL]-1-PIPERAZINYL)DIBENZO[b,f][1,4]THIAZEPINE | SK HOLDINGS CO LTD (KR) | 2010-08-18 | — | — | EP | claimed |
| EP-1644005-B1 | METABOLITE OF QUETIAPINE | ASTRAZENECA AB (SE) | 2010-08-18 | — | — | EP | claimed |
| US-20060229292-A1 | Method of treating childhood disorders | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | US | claimed |
| US-20060217366-A1 | Method of treating schizophrenia and other disorders | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | US | claimed |
| US-20060217365-A1 | Method of treating mood disorders | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | US | claimed |
| US-20060217367-A1 | Method of treating anxiety disorders | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | US | claimed |
| WO-2006077602-A1 | INDUSTRIAL PREPARATION OF 11-[4-{2-(2-HYDROXYETHOXY ETHYL}-1-PIPERAZINYL] DIBENZO [b,f]-1[1, 4] THIAZEPINE | IPCA LABORATORIES LIMITED (IN) | 2006-07-27 | — | — | WO | claimed |
| WO-2006027789-A1 | PROCESS FOR PRODUCING 11-[4-[2-(2-HYDROXYETHOXY)ETHYL]-1-PIPERAZINYL]DIBENZO[b,f][1,4]THIAZEPINE AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | JUBILANT ORGANOSYS LIMITED (IN) | 2006-03-16 | — | — | WO | claimed |
| WO-2006001619-A1 | PROCESS FOR THE PREPARATION OF 11-(4-[2-(2-HYDROXYETHOXY)ETHYL]-I-PIPERAZINYL)DIB ENZO[b,f][l,4]THIAZEPINE | SK CORPORATION (KR) | 2006-01-05 | — | — | WO | claimed |
| EP-1602650-A1 | Method for the preparation of quetiapine by reductive N-alkylation of 11-Piperazinodibenzo(B,F) (1,4)Thioazepin with an aldehyde | Celon Pharma Sp. z o.o. (PL) | 2005-12-07 | — | — | EP | claimed |
| US-20050192268-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS INC. | 2005-09-01 | — | — | US | claimed |
| US-20050026900-A1 | Metabolite | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217365-A1 | Method of treating mood disorders | MC2R, SLC6A11, HSD11B2 | DRD2 238/4885CHRM2 259/4885ADRA2A 201/4885 |
| US-20110136786-A1 | METHOD OF TREATING MOOD DISORDERS | TPH1, TPH2, GABBR1 | DRD2 178/4885CHRM2 2850/4885ADRA2A 471/4885 |
| US-20060217366-A1 | Method of treating schizophrenia and other disorders | SLC6A3, SLC6A1, SLC6A11 | DRD2 17/4885CHRM2 152/4885ADRA2A 291/4885 |
| US-20110136785-A1 | METHOD OF TREATMENT | SLC6A2, SLC6A3, DRD2 | DRD2 3/4885CHRM2 92/4885ADRA2A 74/4885 |
| US-20110144089-A1 | METHOD OF TREATING SCHIZOPHRENIA AND OTHER DISORDERS | SLC6A3, SLC6A1, SLC6A11 | DRD2 17/4885CHRM2 152/4885ADRA2A 291/4885 |
| US-20060217367-A1 | Method of treating anxiety disorders | SLC6A1, SLC6A11, GABRA6 | DRD2 226/4885CHRM2 1904/4885ADRA2A 45/4885 |
| US-20050026900-A1 | Metabolite | BDNF, SLC18A2, SLC6A2 | DRD2 35/4885CHRM2 290/4885ADRA2A 264/4885 |
| US-20110237568-A1 | CRYSTALLINE FORMS | CYP4B1, ABCG2, CYP4F11 | DRD2 2648/4885CHRM2 1561/4885ADRA2A 516/4885 |
| US-20110144088-A1 | METHOD OF TREATING SLEEP DISORDERS | SMPD4, HCRTR2, MTNR1B | DRD2 281/4885CHRM2 18/4885ADRA2A 76/4885 |
| US-20050192268-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | CHRM4, CHRM5, CHRNA10 | DRD2 31/4885CHRM2 6/4885ADRA2A 49/4885 |
| US-20110136784-A1 | Method of Treating Anxiety Disorders | SLC6A1, SLC6A11, GABRA6 | DRD2 226/4885CHRM2 1904/4885ADRA2A 45/4885 |
| US-20060229292-A1 | Method of treating childhood disorders | SLC6A3, SLC6A1, SLC18A2 | DRD2 129/4885CHRM2 2396/4885ADRA2A 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.